First-of-Its-Kind
ND10 is the first oral medication specifically formulated to prevent UV-B cataracts, setting it apart from existing treatments and positioning it as a pioneer in cataract prevention.
Current Treatment Limitations
Cataracts are currently managed only through surgical intervention, with no effective non-surgical methods available. ND10 addresses this gap by providing a potential preventative solution.
Potential for Widespread Adoption
With its oral formulation and preventive capabilities, ND10 has the potential to be adopted by a broad demographic, from those with high UV exposure to individuals looking to proactively manage their eye health.
The UV-B rays at the wavelength of 280-315nm can put your eyes at risk by increasing the likelihood of developing UV cataracts due to the gradual accumulation of UV radiation exposure over the years.
Our innovative product ND10 under development represents a pioneering approach as the novel oral medication designed to prevent UV-B cataracts. The proposed mechanism is that ND10 leverages its antioxidant properties to play a pivotal role in averting this preventable.